Parkinson's drug tested for eye disease
NCT ID NCT03197493
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a drug called carbidopa-levodopa (Sinemet), typically used for Parkinson's disease, in people with wet age-related macular degeneration (AMD). It is a 9-month extension for 35 participants who completed an earlier study. The goal is to see if the drug can help maintain vision and reduce retinal swelling.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- carbidopa-levodopa (Sinemet)
- What this could lead to
- If it works, this could point toward a new oral treatment to help control vision loss in wet age-related macular degeneration.
- What could go wrong
- This is a small, early-phase extension study with only 35 participants. It may not show clear benefits, and the drug can cause side effects like nausea or dizziness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULA; DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Robert W Snyder, MD, PhD, PC
Tucson, Arizona, 85712, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection save vision in wet AMD?
- Eye injection aims to tame leading causes of blindness
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
- New eye drug aims to save sight in wet AMD
- Withdrawn study sought better way to time eye injections